Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
Giuseppe Luigi Banna, Mohd Ali Hassan, Alessio Signori, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e246837-e246837
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1373-1414
Open Access | Times Cited: 25
A Lung CT Foundation Model Facilitating Disease Diagnosis and Medical Imaging
Zebin Gao, Guoxun Zhang, Hengrui Liang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access | Times Cited: 1
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer
Stephanie P.L. Saw, Wen‐Zhao Zhong, Rui Fu, et al.
Lung Cancer (2025) Vol. 200, pp. 108076-108076
Open Access
Cytokine profile of bronchoalveolar lavage in patients with and without checkpoint inhibitor pneumonitis
Michelle Ploch, Songzhu Zhao, Lai Wei, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Evidence for a reduction in number of cycles of immune checkpoint inhibitors
Abdul-Hamid Bazarbachi, Nicola Magrini, Zeba Aziz, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. 9-11
Closed Access
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
Angela J. Yoon, Richard D. Carvajal, Evan M. Graboyes, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
A stage IIIA lung adenocarcinoma case achieving pathological response with only one cycle of preoperative nivolumab combination chemotherapy
Shuhei Baba, Fumihiko Kinoshita, Yoshihiro Yamamoto, et al.
General Thoracic and Cardiovascular Surgery Cases (2025) Vol. 4, Iss. 1
Open Access
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
Neoadjuvant chemotherapy and low dose immunotherapy in resectable non-small cell lung cancer – A multi-center retrospective cohort analysis
Minit Shah, Vanita Noronha, Srinivasan Kulandaivel, et al.
Clinical Oncology (2025) Vol. 41, pp. 103795-103795
Closed Access
Carcinoma de pulmón de célula no pequeña
Y. Lage, Miguel García-Pardo, M.E. Olmedo, et al.
Medicine - Programa de Formación Médica Continuada Acreditado (2025) Vol. 14, Iss. 27, pp. 1580-1594
Closed Access
Protocolo de manejo multimodal del cáncer de pulmón: cirugía, radioterapia y tratamiento sistémico. Indicaciones terapéuticas y paliativas de la cirugía y la radioterapia
Jesús Vicente Chamorro, J.C. Calvo, Miguel García-Pardo, et al.
Medicine - Programa de Formación Médica Continuada Acreditado (2025) Vol. 14, Iss. 27, pp. 1622-1626
Closed Access
Eficiência dos inibidores de PD-1 e PD-L1 no tratamento do carcinoma pulmonar de não pequenas células, uma revisão integrativa
Enzo Stella de Carvalho, Lívia Burim Cerreti, Cecília Rioja Gomes, et al.
Caderno Pedagógico (2025) Vol. 22, Iss. 5, pp. e14644-e14644
Closed Access
A system review of neoadjuvant immune checkpoint blockade for breast cancer
Yanle Ye, Zhishan Zhang, Hong Zhao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Where lung cancer and tuberculosis intersect: recent advances
Chunju Fang, Xuanlu He, Fei Tang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Noteworthy in Cardiothoracic Surgery 2024
Christina M. Stuart, Robert A. Meguid, Jessica Y. Rove
Seminars in Cardiothoracic and Vascular Anesthesia (2025)
Closed Access
Real-World Treatment Patterns and Outcomes Among Patients with Early Non-Small Cell Lung Cancer
Jennifer D. Deem, Zsolt Hepp, Joshua J. Carlson
Current Oncology (2025) Vol. 32, Iss. 4, pp. 239-239
Open Access
Outcomes of urgent lung transplantation in critically ill patients versus standard lung transplantation: A systematic review and meta-analysis
Xiaohan Jin, Hao‐Ji Yan, Zeng-Wei Yu, et al.
Transplantation Reviews (2025) Vol. 39, Iss. 3, pp. 100933-100933
Closed Access
Stage I and II nonsmall cell lung cancer treatment options
Georgia Hardavella, Dimitrios E. Magouliotis, Roberto Chalela, et al.
Breathe (2024) Vol. 20, Iss. 2, pp. 230219-230219
Open Access | Times Cited: 3
Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials
Kaiqi Chen, Xin Wei Wang, Rui Yue, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis
Dun‐Chang Mo, Jianfeng Huang, Peng Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
What Does N2 Lymph Node Involvement Mean for Patients with Non-Small Cell Lung Cancer (NSCLC)?—A Review of Implications for Diagnosis and Treatment
Julio David Linares Díaz, John Edwards, Anne-Leen Deleu, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2673-2673
Open Access | Times Cited: 1
Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials
Hai Huang, Lianyun Li, Ling Tong, et al.
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0310808-e0310808
Open Access | Times Cited: 1
Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements
Alejandra Martínez‐Pérez, Rocío Granda‐Díaz, Candelaria Aguilar-García, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Evaluation of the Immune Response within the Tumor Microenvironment in African American and Non-Hispanic White Patients with Non–Small Cell Lung Cancer
Matthew R. Trendowski, Donovan Watza, Christine M. Lusk, et al.
Cancer Epidemiology Biomarkers & Prevention (2024) Vol. 33, Iss. 9, pp. 1220-1228
Closed Access
A Response Letter by Cameron et al
Robert B. Cameron, Jacobi Hines, Valter Torri, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 8, pp. e26-e28
Closed Access
Page 1 - Next Page

Scroll to top